TandemAI

TandemAI is a pioneering technology company dedicated to transforming global drug discovery through the seamless integration of advanced AI, physics-based computational methods, and wet lab experimentation. The company's mission is to make cutting-edge drug discovery technologies accessible to all — from seasoned computational chemists to teams new to the field — by delivering an all-encompassing, ready-to-use platform that accelerates research and reduces cost.

Headquartered with a global presence spanning the US and China, TandemAI employs over 350 drug discovery experts, including more than 50 top-tier AI and computational chemistry scientists. The company has established over 100 successful partnerships and serves a diverse roster of more than 80 clients worldwide, offering both FTE-based pricing models that bundle wet lab services with complimentary access to AI and computational tools, and stand-alone SaaS software licensing.

TandemViz™ Platform

• TandemViz™ is TandemAI's next-generation, cloud-enabled, browser-based graphical user interface designed for integrated drug discovery.
• It allows users to create, manage, and share drug discovery research pipelines in a single, user-friendly workspace.
• The platform facilitates effortless collaboration with internal teams, external partners, and TandemAI's own experts.
• TandemViz™ provides easy access to high-performance computation resources and streamlined data consolidation for drug discovery projects.
• It supports the full range of workflows, from advanced computational analyses to managing wet lab experiments and streamlining data analysis.
• The platform is accessible to both experts and those new to computational chemistry, democratizing access to state-of-the-art tools.
• TandemViz™ 1.0 was officially released in March 2023 as a web-based graphical user interface for seamless integration of computational analyses and experimental data.

Computational Drug Discovery Capabilities

• TandemAI deploys over 30 validated computational drug discovery tools powered by proprietary algorithms combining physics-based and AI approaches.
• Hit Finding services help identify promising candidate molecules from large chemical spaces.
• Hit and Lead Optimization services refine and improve candidate compounds toward drug-like properties.
• The platform leverages in-house high-performance computation resources to support demanding computational workloads.
• Physics-based methods such as Free Energy Perturbation (FEP) are available for tasks including core hop evaluations.

Wet Lab and Experimental Services

• TandemAI offers premium wet lab services that are fully integrated with its computational platform, enabling a truly end-to-end drug discovery workflow.
• Biological assays are available to support experimental validation of computational findings.
• Medicinal chemistry and synthesis services are provided to support compound design and preparation.
• Digital assays and workflow management tools help teams streamline and track experimental processes.

Peptide Platform

• TandemAI operates a dedicated Peptide Platform led by Chief Science Officer Ved Srivastava, Ph.D., who brings over 25 years of experience in peptide drug discovery and development.
• The team has a track record of advancing first-in-class therapies, including Byetta™, Symlin™, Bydureon™, and Myalepta™.
• The platform supports peptide-focused drug discovery and development programs for partners and clients.

Leadership and Team

• Co-Founder and CEO Jeff He, MBA, brings 20+ years of experience in corporate strategy, business development, venture financing, and biotech operations.
• Co-Founder and Executive Chairman Lanny Sun founded Silicon Therapeutics and led the company through its $2 billion acquisition by Roivant Sciences.
• Chief Technology Officer Albert Pan, Ph.D., has deep expertise in computational biochemistry and spent 12 years as a senior scientist at D. E. Shaw Research; he holds degrees from Harvard and UC Berkeley.
• President of R&D Kerry Blanchard, M.D., Ph.D., is a global biopharmaceutical leader with 40+ years of experience, having previously served as CEO of Everest Medicines and in senior roles at Innovent Biologics and Eli Lilly.
• CSO of Peptide Ved Srivastava, Ph.D., is a co-founder of Phoundry Pharma and former Head of Peptide Chemistry at GSK and Amylin.

Company Milestones and Funding

• In November 2025, TandemAI closed a $22 million Series A Extension Round to accelerate AI-driven drug discovery.
• In July 2025, TandemAI and Perpetual Medicines announced a strategic merger to expand physics- and AI-based drug discovery capabilities.
• The company continues to expand its platform, team, and partnerships with a commitment to continual technological advancement.

TandemAI's integrated approach — combining proprietary AI and physics-based algorithms, high-performance computing, wet lab operations, and the TandemViz™ collaboration platform — positions it as a comprehensive partner for pharmaceutical and biotech organizations seeking to accelerate and modernize their drug discovery programs.